Skip to main content

Table 1 Baseline characteristics of the TACE/TAE+ SBRT and SBRT groups

From: Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm

  TACE/TAE + SBRT
(n = 77)
SBRT
(n = 50)
P value
Age ≥60/<60 years 60/17 39/11 0.992
Gender (male/female) 67/10 45/5 0.610
HBsAg (unknown/negative/positive) 0/4/73 2/4/44 0.456
CTP class (A/B) 70/7 41/9 0.139
ECOG (0/1) 60/17 39/11 0.545
Nodules (solitary/multiple) 50/27 37/13 0.283
Recurrent/Primary 10/67 5/45 0.324
BCLC (A/B) 50/27 37/13 0.283
Liver cirrhosis (Yes/No) 57/20 38/12 0.485
AFP ≥100 ng/mL (Yes/No) 44/33 30/20 0.562
Tumor size (5–10 cm/≥10 cm) 51/26 43/7 0.013*
EQD2 (≥/<74Gy) 49/28 43/7 0.150
BED10 (≥/<100Gy) 24/53 21/29 0.031*
30-45Gy/3Fr;38-48Gy/4Fr;35-50Gy/5Fr 43/23/11 31/15/4 0.695
  1. AFP alpha fetoprotein, BED biologically effective dose, BCLC Barcelona clinic liver cancer, CTP Child–Turcotte–Pugh, EQD 2 equivalent dose in 2Gy fraction, ECOG Eastern cooperative oncology group, Fr fractions, SBRT stereotactic body radiation therapy, TACE/TAE trans-arterial embolization; *P < 0.05